Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 40-46

  Van De Wetering, Jacqueline ^a   Koumoutsakos, Periklis ^a   Peeters, Annemiek ^a   Van Der Mast, Barbara J ^a   De Kuiper, Petronella ^a   IJzermans, Jan N ^b   Weimar, Willem ^a   Baan, Carla C ^a  

^a Departments of Internal Medicine   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Calcineurin; Discontinuation; FOXP3; Inhibitors; T cells

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN; CYCLOSPORIN A; FAS ANTIGEN; FAS LIGAND; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PERFORIN; PREDNISONE; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

APOPTOSIS; ARTICLE; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; GENE EXPRESSION; GRAFT RECIPIENT; HUMAN; IMMUNOREACTIVITY; IMMUNOREGULATION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY T LYMPHOCYTE; SYSTOLIC BLOOD PRESSURE; TH1 CELL; TH17 CELL; TH2 CELL;

APOPTOSIS; BIOLOGICAL MARKERS; CALCINEURIN; CYCLOSPORINE; CYTOKINES; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME;

EID: 79551714779     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01311.x     Document Type: Article

References (26)

1. Kasiske BL, Gaston RS, Gourishankar S et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005: 5: 1405.
2. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004: 78: 1653.
3. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005: 352: 1371.
4. Van Der Mast BJ, Rischen-Vos J, De Kuiper P, Vaessen LM, Van Besouw NM, Weimar W. Calcineurin inhibitor withdrawal in stable kidney transplant patients decreases the donor-specific cytotoxic T lymphocyte precursor frequency. Transplantation 2005: 80: 1220.
5. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000: 11: 1910.
6. Smak Gregoor PJ, De Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002: 13: 1365.
7. Smak Gregoor PJ, Van Gelder T, Van Besouw NM, Van Der Mast BJ, JN IJ, Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000: 70: 143.
8. Van Der Mast BJ, Van Besouw NM, De Kuiper P et al. Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppression. Transplantation 2001: 72: 873.
9. Van Besouw NM, Van Der Mast BJ, De Kuiper P et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000: 70: 136.
10. Baan CC, Van Der Mast BJ, Klepper M et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005: 80: 110.
11. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004: 4: 665.
12. Van De Wetering J, Van Der Mast BJ, De Kuiper P et al. Reduction of immunosuppressive load in renal transplant recipients with a low donor-specific cytotoxic T-lymphocyte precursor frequency is safe. Transplant Proc 2005: 37: 779.
13. Strijbosch LW, Does RJ, Buurman WA. Computer aided design and evaluation of limiting and serial dilution experiments. Int J Biomed Comput 1988: 23: 279.
14. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000: 25: 169.
15. Wu J, Zhu YH, Patel SB. Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2. Am J Physiol 1999: 277: E1087.
16. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997: 12: 375.
17. Fernandez MA, Puttur FK, Wang YM, Howden W, Alexander SI, Jones CA. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J Immunol 2008: 180: 1556.
18. Franzese O, Kennedy PT, Gehring AJ et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005: 79: 3322.
19. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003: 3: 147.
20. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000: 80: 1483.
21. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 1998: 273: 13367.
22. Kronke M, Leonard WJ, Depper JM et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A 1984: 81: 5214.
23. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992: 357: 695.
24. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002: 2: 37.
25. Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+ Foxp3+ regulatory T cell development. J Immunol 2008: 181: 3285.
26. Koenen HJ, Fasse E, Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005: 174: 7573.